PET/CT, MR, and PET/MR in Lymphoma and Melanoma
With the introduction of hybrid imaging technologies such as PET/CT and recently PET/MRI, staging and therapy-response monitoring have evolved. PET/CT has been shown to be of value for routine staging of FDG-avid lymphomas before as well as at the end of treatment. For interim staging, trials are on...
Gespeichert in:
| Veröffentlicht in: | Seminars in nuclear medicine 2015-07, Vol.45 (4), p.322-331 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 331 |
|---|---|
| container_issue | 4 |
| container_start_page | 322 |
| container_title | Seminars in nuclear medicine |
| container_volume | 45 |
| creator | Schwenzer, Nina F., MD Pfannenberg, Anna Christina, MD |
| description | With the introduction of hybrid imaging technologies such as PET/CT and recently PET/MRI, staging and therapy-response monitoring have evolved. PET/CT has been shown to be of value for routine staging of FDG-avid lymphomas before as well as at the end of treatment. For interim staging, trials are ongoing to evaluate the use of PET/CT. In melanoma, PET/CT can be recommended for stages III and IV diseases for initial staging and before surgery. Studies investigating the use of PET/CT for early therapy response are promising. The role of PET/MR in lymphoma and melanoma imaging has to be defined because no larger studies exist so far. There may be an application of PET/MR in research especially for tumor characterization and therapy response. Furthermore, the potential role of non-FDG tracers is elucidated regarding the assessment of treatment response in targeted drug regimens. |
| doi_str_mv | 10.1053/j.semnuclmed.2015.03.006 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1702653006</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S000129981500046X</els_id><sourcerecordid>1702653006</sourcerecordid><originalsourceid>FETCH-LOGICAL-c429t-10ca91f83cd5646e64ac8169c69d4bbdcc8e1c2489b07f3a99e20467eabcca5a3</originalsourceid><addsrcrecordid>eNqNkUtP4zAQxy0EWgrsV0A5ciDp2I7d-IIEVXlIrVixRdqb5UymwiWPEjdI_fYkWxDSnvZkz8x_Xr9hLOKQcFByvE4CVXWHZUVFIoCrBGQCoA_YiCuVxakW8pCNAIDHwpjsmJ2EsAYQShn1gx0LDQq0MiM2_jVbjqfLy2jxdBm5uogGe_EU-Tqa76rNS1O5v-4Fla7ujTN2tHJloJ-f7yl7vp0tp_fx_PHuYXo9jzEVZhtzQGf4KpNYKJ1q0qnDjGuD2hRpnheIGXEUaWZymKykM4YEpHpCLkd0yslTdrGvu2mbt47C1lY-IJX9FNR0wfIJCK1kv3MvzfZSbJsQWlrZTesr1-4sBzvgsmv7jcsOuCxIu089_-zS5UPsK_GLTy-42Quo3_XdU2sDeqqRCt8Sbm3R-P_pcvVPESx97dGVr7SjsG66tu5ZWm6DsGB_D2cbrsZV_0v1H_kBT8OSnQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1702653006</pqid></control><display><type>article</type><title>PET/CT, MR, and PET/MR in Lymphoma and Melanoma</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Schwenzer, Nina F., MD ; Pfannenberg, Anna Christina, MD</creator><creatorcontrib>Schwenzer, Nina F., MD ; Pfannenberg, Anna Christina, MD</creatorcontrib><description>With the introduction of hybrid imaging technologies such as PET/CT and recently PET/MRI, staging and therapy-response monitoring have evolved. PET/CT has been shown to be of value for routine staging of FDG-avid lymphomas before as well as at the end of treatment. For interim staging, trials are ongoing to evaluate the use of PET/CT. In melanoma, PET/CT can be recommended for stages III and IV diseases for initial staging and before surgery. Studies investigating the use of PET/CT for early therapy response are promising. The role of PET/MR in lymphoma and melanoma imaging has to be defined because no larger studies exist so far. There may be an application of PET/MR in research especially for tumor characterization and therapy response. Furthermore, the potential role of non-FDG tracers is elucidated regarding the assessment of treatment response in targeted drug regimens.</description><identifier>ISSN: 0001-2998</identifier><identifier>EISSN: 1558-4623</identifier><identifier>DOI: 10.1053/j.semnuclmed.2015.03.006</identifier><identifier>PMID: 26050659</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Animals ; Humans ; Lymphoma - diagnosis ; Lymphoma - pathology ; Lymphoma - surgery ; Lymphoma - therapy ; Magnetic Resonance Imaging - methods ; Melanoma - diagnosis ; Melanoma - pathology ; Melanoma - surgery ; Melanoma - therapy ; Multimodal Imaging - methods ; Positron-Emission Tomography - methods ; Radiology ; Tomography, X-Ray Computed - methods</subject><ispartof>Seminars in nuclear medicine, 2015-07, Vol.45 (4), p.322-331</ispartof><rights>Elsevier Inc.</rights><rights>2015 Elsevier Inc.</rights><rights>Copyright © 2015 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c429t-10ca91f83cd5646e64ac8169c69d4bbdcc8e1c2489b07f3a99e20467eabcca5a3</citedby><cites>FETCH-LOGICAL-c429t-10ca91f83cd5646e64ac8169c69d4bbdcc8e1c2489b07f3a99e20467eabcca5a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S000129981500046X$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26050659$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Schwenzer, Nina F., MD</creatorcontrib><creatorcontrib>Pfannenberg, Anna Christina, MD</creatorcontrib><title>PET/CT, MR, and PET/MR in Lymphoma and Melanoma</title><title>Seminars in nuclear medicine</title><addtitle>Semin Nucl Med</addtitle><description>With the introduction of hybrid imaging technologies such as PET/CT and recently PET/MRI, staging and therapy-response monitoring have evolved. PET/CT has been shown to be of value for routine staging of FDG-avid lymphomas before as well as at the end of treatment. For interim staging, trials are ongoing to evaluate the use of PET/CT. In melanoma, PET/CT can be recommended for stages III and IV diseases for initial staging and before surgery. Studies investigating the use of PET/CT for early therapy response are promising. The role of PET/MR in lymphoma and melanoma imaging has to be defined because no larger studies exist so far. There may be an application of PET/MR in research especially for tumor characterization and therapy response. Furthermore, the potential role of non-FDG tracers is elucidated regarding the assessment of treatment response in targeted drug regimens.</description><subject>Animals</subject><subject>Humans</subject><subject>Lymphoma - diagnosis</subject><subject>Lymphoma - pathology</subject><subject>Lymphoma - surgery</subject><subject>Lymphoma - therapy</subject><subject>Magnetic Resonance Imaging - methods</subject><subject>Melanoma - diagnosis</subject><subject>Melanoma - pathology</subject><subject>Melanoma - surgery</subject><subject>Melanoma - therapy</subject><subject>Multimodal Imaging - methods</subject><subject>Positron-Emission Tomography - methods</subject><subject>Radiology</subject><subject>Tomography, X-Ray Computed - methods</subject><issn>0001-2998</issn><issn>1558-4623</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkUtP4zAQxy0EWgrsV0A5ciDp2I7d-IIEVXlIrVixRdqb5UymwiWPEjdI_fYkWxDSnvZkz8x_Xr9hLOKQcFByvE4CVXWHZUVFIoCrBGQCoA_YiCuVxakW8pCNAIDHwpjsmJ2EsAYQShn1gx0LDQq0MiM2_jVbjqfLy2jxdBm5uogGe_EU-Tqa76rNS1O5v-4Fla7ujTN2tHJloJ-f7yl7vp0tp_fx_PHuYXo9jzEVZhtzQGf4KpNYKJ1q0qnDjGuD2hRpnheIGXEUaWZymKykM4YEpHpCLkd0yslTdrGvu2mbt47C1lY-IJX9FNR0wfIJCK1kv3MvzfZSbJsQWlrZTesr1-4sBzvgsmv7jcsOuCxIu089_-zS5UPsK_GLTy-42Quo3_XdU2sDeqqRCt8Sbm3R-P_pcvVPESx97dGVr7SjsG66tu5ZWm6DsGB_D2cbrsZV_0v1H_kBT8OSnQ</recordid><startdate>20150701</startdate><enddate>20150701</enddate><creator>Schwenzer, Nina F., MD</creator><creator>Pfannenberg, Anna Christina, MD</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20150701</creationdate><title>PET/CT, MR, and PET/MR in Lymphoma and Melanoma</title><author>Schwenzer, Nina F., MD ; Pfannenberg, Anna Christina, MD</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c429t-10ca91f83cd5646e64ac8169c69d4bbdcc8e1c2489b07f3a99e20467eabcca5a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Animals</topic><topic>Humans</topic><topic>Lymphoma - diagnosis</topic><topic>Lymphoma - pathology</topic><topic>Lymphoma - surgery</topic><topic>Lymphoma - therapy</topic><topic>Magnetic Resonance Imaging - methods</topic><topic>Melanoma - diagnosis</topic><topic>Melanoma - pathology</topic><topic>Melanoma - surgery</topic><topic>Melanoma - therapy</topic><topic>Multimodal Imaging - methods</topic><topic>Positron-Emission Tomography - methods</topic><topic>Radiology</topic><topic>Tomography, X-Ray Computed - methods</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Schwenzer, Nina F., MD</creatorcontrib><creatorcontrib>Pfannenberg, Anna Christina, MD</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Seminars in nuclear medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Schwenzer, Nina F., MD</au><au>Pfannenberg, Anna Christina, MD</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>PET/CT, MR, and PET/MR in Lymphoma and Melanoma</atitle><jtitle>Seminars in nuclear medicine</jtitle><addtitle>Semin Nucl Med</addtitle><date>2015-07-01</date><risdate>2015</risdate><volume>45</volume><issue>4</issue><spage>322</spage><epage>331</epage><pages>322-331</pages><issn>0001-2998</issn><eissn>1558-4623</eissn><abstract>With the introduction of hybrid imaging technologies such as PET/CT and recently PET/MRI, staging and therapy-response monitoring have evolved. PET/CT has been shown to be of value for routine staging of FDG-avid lymphomas before as well as at the end of treatment. For interim staging, trials are ongoing to evaluate the use of PET/CT. In melanoma, PET/CT can be recommended for stages III and IV diseases for initial staging and before surgery. Studies investigating the use of PET/CT for early therapy response are promising. The role of PET/MR in lymphoma and melanoma imaging has to be defined because no larger studies exist so far. There may be an application of PET/MR in research especially for tumor characterization and therapy response. Furthermore, the potential role of non-FDG tracers is elucidated regarding the assessment of treatment response in targeted drug regimens.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>26050659</pmid><doi>10.1053/j.semnuclmed.2015.03.006</doi><tpages>10</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0001-2998 |
| ispartof | Seminars in nuclear medicine, 2015-07, Vol.45 (4), p.322-331 |
| issn | 0001-2998 1558-4623 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1702653006 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete |
| subjects | Animals Humans Lymphoma - diagnosis Lymphoma - pathology Lymphoma - surgery Lymphoma - therapy Magnetic Resonance Imaging - methods Melanoma - diagnosis Melanoma - pathology Melanoma - surgery Melanoma - therapy Multimodal Imaging - methods Positron-Emission Tomography - methods Radiology Tomography, X-Ray Computed - methods |
| title | PET/CT, MR, and PET/MR in Lymphoma and Melanoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-11T17%3A30%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=PET/CT,%20MR,%20and%20PET/MR%20in%20Lymphoma%20and%20Melanoma&rft.jtitle=Seminars%20in%20nuclear%20medicine&rft.au=Schwenzer,%20Nina%20F.,%20MD&rft.date=2015-07-01&rft.volume=45&rft.issue=4&rft.spage=322&rft.epage=331&rft.pages=322-331&rft.issn=0001-2998&rft.eissn=1558-4623&rft_id=info:doi/10.1053/j.semnuclmed.2015.03.006&rft_dat=%3Cproquest_cross%3E1702653006%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1702653006&rft_id=info:pmid/26050659&rft_els_id=1_s2_0_S000129981500046X&rfr_iscdi=true |